東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Engineered Proteins to NKP46 for Can...

Lee, Robert Benjamin,

FindBook

Google Book

Amazon

博客來

Engineered Proteins to NKP46 for Cancer Therapeutics /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Engineered Proteins to NKP46 for Cancer Therapeutics // Robert Benjamin Lee.
作者:	Lee, Robert Benjamin,
面頁冊數:	1 electronic resource (130 pages)
附註:	Source: Dissertations Abstracts International, Volume: 86-10, Section: B.
Contained By:	Dissertations Abstracts International86-10B.
標題:	Cancer. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31974652
ISBN:	9798311952521

Engineered Proteins to NKP46 for Cancer Therapeutics /
Lee, Robert Benjamin,

Engineered Proteins to NKP46 for Cancer Therapeutics /Robert Benjamin Lee. - 1 electronic resource (130 pages)

Source: Dissertations Abstracts International, Volume: 86-10, Section: B.

NKp46 (NCR1, CD335) is an activating receptor expressed on the surface of natural killer (NK) cells in the immune system. NKp46 has been the target of NK cell engaging bispecific antibodies in recent years, with multiple studies demonstrating the potential of engaging NKp46 for antitumor responses in cancer. In this thesis, I discuss the discovery and engineering of antibodies and fibronectin domain proteins that bind to either human NKp46, mouse NKp46, or both using phage display and yeast surface display. One species cross-reactive antibody was epitope mapped to conserved mouse and human amino acid residues and could induce NK cell proliferation and activation. A panel of NK cell engager (NKCE) bispecific antibody constructs was created from binders of both NKp46 and the tumor antigen CD20 to explore NCKE configurations, valency, and Fc effector functions. NKp46 engagement with the bispecific antibodies was shown to increase NK cell cytotoxicity against tumor cells as compared to the anti-CD20 antibody alone in an Fc-independent manner. This thesis contributes to a body of work related to NKp46, NCKEs, and cancer therapeutics, and provides a number of proteins as useful tools for basic science and translational applications.

English

ISBN: 9798311952521Subjects--Topical Terms:

634186
Cancer.

Engineered Proteins to NKP46 for Cancer Therapeutics /
LDR:02577nmm a22003853i 4500 001 2436588
005 20251023121251.5
006 m o d
007 cr|nu||||||||
008 261011s2024 miu||||||m |||||||eng d
020 $a 9798311952521
035 $a (MiAaPQD)AAI31974652
035 $a (MiAaPQD)Stanfordvd690jd0116
035 $a AAI31974652
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Lee, Robert Benjamin, $e author. $3 3827306
245 1 0 $a Engineered Proteins to NKP46 for Cancer Therapeutics / $c Robert Benjamin Lee.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2024
300 $a 1 electronic resource (130 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 86-10, Section: B.
500 $a Advisors: Cochran, Jennifer; Swartz, James Committee members: Sunwoo, John; Bent, Stacey F.
502 $b Ph.D. $c Stanford University $d 2024.
520 $a NKp46 (NCR1, CD335) is an activating receptor expressed on the surface of natural killer (NK) cells in the immune system. NKp46 has been the target of NK cell engaging bispecific antibodies in recent years, with multiple studies demonstrating the potential of engaging NKp46 for antitumor responses in cancer. In this thesis, I discuss the discovery and engineering of antibodies and fibronectin domain proteins that bind to either human NKp46, mouse NKp46, or both using phage display and yeast surface display. One species cross-reactive antibody was epitope mapped to conserved mouse and human amino acid residues and could induce NK cell proliferation and activation. A panel of NK cell engager (NKCE) bispecific antibody constructs was created from binders of both NKp46 and the tumor antigen CD20 to explore NCKE configurations, valency, and Fc effector functions. NKp46 engagement with the bispecific antibodies was shown to increase NK cell cytotoxicity against tumor cells as compared to the anti-CD20 antibody alone in an Fc-independent manner. This thesis contributes to a body of work related to NKp46, NCKEs, and cancer therapeutics, and provides a number of proteins as useful tools for basic science and translational applications.
546 $a English
590 $a School code: 0212
650 4 $a Cancer. $3 634186
650 4 $a Monoclonal antibodies. $3 603890
650 4 $a Monkeys & apes. $3 3681351
650 4 $a Cytotoxicity. $3 3682273
650 4 $a Mutation. $3 837917
650 4 $a Amino acids. $3 558768
650 4 $a E coli. $3 3556834
650 4 $a Toxicology. $3 556884
650 4 $a Yeast. $3 621059
650 4 $a Mutagenesis. $3 754710
650 4 $a T cell receptors. $3 3561758
650 4 $a Plasmids. $3 3319070
650 4 $a Cloning. $3 571606
650 4 $a Medical research. $2 bicssc $3 1556686
650 4 $a Lymphocytes. $3 895384
650 4 $a Clinical trials. $3 724498
650 4 $a Glucose. $3 2084335
650 4 $a Engineering. $3 586835
650 4 $a Antigens. $3 700737
650 4 $a Tumors. $3 893964
690 $a 0383
690 $a 0537
710 2 $a Stanford University. $e degree granting institution. $3 3765820
720 1 $a Cochran, Jennifer $e degree supervisor.
720 1 $a Swartz, James $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 86-10B.
790 $a 0212
791 $a Ph.D.
792 $a 2024
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31974652